|
Abstract
Blood product belongs to biological products and is a biological active preparation which collects healthy blood as the raw material and then is made through biological process or separation and purification technologies. Blood products are irreplaceable in the application of medical emergency and prevention & treatment to some specific diseases.
China blood product industry is about to see a fast and steady growth: due to the increasing population, high incidence rate of malignant disease and growing national economy, blood product market demands are expected to remain growing at 15% annually; China didn’t approve to found new blood product enterprises since 2001, which together with imports limit creates a relatively stable competition environment; after plasma collection stations got restructured, blood product industry chain has become more flexible, which is favor to a long-term development; and industrial supervision will be increasingly strict.
Since the state started regulating plasma collection stations in 2004, plasma volume collected has been sliding, to 3,000 tons in 2005 and 2006. As plasma collection stations finished the restructuring, the plasma volume collected has been gradually increasing but plasma supply still falls short presently. The supply and demand are expected to come to a balance by 2008.
Trend of Plasma Volume Collected in China, 2001-2008
When the restructuring is over, plasma volume collected is ready to still play an important role for the blood product enterprises to get developed but more important is the ability to manage plasma source. Plasma source management is mainly focused on plasma source scale management and plasma source quality control. Plasma source quality is measured by collected volume of featured plasma, plasma donors’ management and guarantee to plasma security.
Plasma price keeps growing steadily even after plasma collection stations are restructured, which is because, on the one hand, plasma supply is gradually coming back but still in short; on the other hand, plasma price is quite transparent and even if the cost is added under the counter, it can be seen on the final price.
China still can’t meet the demands for plasma during 2006-2008 periods; as a result, human serum albumin price will keep high during 2007-2008 periods.
Leading enterprises have fostered strong competitive advantages from upstream—quantity, quality and management of plasma collection stations to downstream products’ R & D, production and distribution. There will form 2-3 nationwide leader and 5-6 regional leaders in China blood product industry in the future while those small weak enterprises will be phased out.
Table of content
1 Overview of development environments of China blood product industry
1.1 Restructuring of plasma collection stations
1.2 Profitability environments
1.3 Industrial supervision gets increasingly strict
2 China blood product market
2.1 Plasma volume collected
2.2 Plasma price
2.3 Human serum albumin price
2.4 Competition pattern
3 Key blood product enterprises of China
3.1 Hualan Biological Engineering Inc.
3.2 Shanghai RAAS Blood Products Co., Ltd
3.3 Rongsheng Pharmaceuticals
3.4 Shanghai Institute of Biological Products
Selected charts
Market structure of raw plasma volume used in China, 2005
Product lines of domestic key blood product enterprises
Blood product industry chain before the restructuring of plasma collection stations
Blood product industry chain after the restructuring of plasma collection stations
Trend of plasma volume collected in China, 2001-2008
Plasma price trend of China, 1994-2008
Price trend of human serum albumin in China, 1994-2006
Oligarch monopoly pattern of China blood product industry
|
Published Time |
Pages |
Publisher |
Price |
|
Apr/2007 |
25 |
ResearchInChina |
$399 (PDF) |
|
$399 (Hard Copy) |
|
您现在的位置： 
